In a newly diagnosed metastatic gastric cancer patient, what chemotherapy regimens are recommended and what baseline investigations should be performed prior to initiating therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Chemotherapy Regimens for Newly Diagnosed Metastatic Gastric Cancer

First-Line Treatment Selection

For newly diagnosed metastatic gastric cancer, your chemotherapy regimen must be selected based on HER2 status, PD-L1 expression (CPS score), and MSI/dMMR status—these biomarkers are mandatory before starting any treatment.

Treatment Algorithm by Biomarker Status:

HER2-Positive Disease (IHC 3+ or IHC 2+/FISH+) with PD-L1 CPS ≥1:

Pembrolizumab + trastuzumab + fluoropyrimidine (5-FU or capecitabine) + platinum (cisplatin or oxaliplatin) is the preferred first-line regimen 1. This quadruplet combination achieved median OS of 20 months versus 16.9 months with chemotherapy plus trastuzumab alone in KEYNOTE-811, with improved response rates (72.6% vs 59.8%) 1. This is FDA-approved and represents a Category 1 recommendation.

  • If PD-L1 CPS <1: Use trastuzumab + cisplatin + fluoropyrimidine (capecitabine or 5-FU) without immunotherapy 2, 1

HER2-Negative Disease with PD-L1 CPS ≥5:

Pembrolizumab + fluoropyrimidine + platinum-based chemotherapy is the preferred Category 1 regimen 1. The KEYNOTE-859 trial demonstrated median OS of 15.7 months versus 11.8 months with chemotherapy alone in the PD-L1 CPS ≥10 subgroup (HR 0.65, P <0.0001) 1.

  • For PD-L1 CPS 1-4: Pembrolizumab + chemotherapy is still preferred but with slightly less robust benefit (median OS 13 vs 11.4 months) 1
  • For PD-L1 CPS <1: Use chemotherapy alone (fluoropyrimidine + platinum doublet)

MSI-H/dMMR Tumors (Any Line):

Pembrolizumab monotherapy should be the first choice 2, 1. The KEYNOTE-158 trial showed unprecedented ORR of 45.8% and median PFS of 11 months with pembrolizumab monotherapy in MSI-H gastric cancer—results never achieved with chemotherapy 2. This represents a paradigm shift where immunotherapy alone outperforms chemotherapy.

HER2-Negative, PD-L1 Low/Negative, MSS:

Use fluoropyrimidine + platinum doublet chemotherapy. Common regimens include:

  • FOLFOX (5-FU + oxaliplatin)
  • CAPOX (capecitabine + oxaliplatin)
  • Cisplatin + 5-FU or capecitabine

Three-drug combinations (adding docetaxel or epirubicin) increase response rates but also toxicity without substantial survival benefit when second-line therapy is available 3.


Baseline Investigations Required Before Starting Chemotherapy

Mandatory Biomarker Testing:

  1. HER2 status (IHC and FISH if IHC 2+): Essential for trastuzumab eligibility. Patients with IHC 3+ or IHC 2+/FISH+ derive maximum benefit (median OS 16 vs 11.8 months with trastuzumab) 1
  2. PD-L1 CPS score: Required for pembrolizumab decision-making. CPS ≥5 represents the strongest evidence for benefit 1
  3. MSI/dMMR status: Identifies patients who should receive pembrolizumab monotherapy instead of chemotherapy 2, 1

Staging and Extent of Disease:

  • High-resolution CT chest, abdomen, and pelvis: Assess metastatic burden and identify oligometastatic disease 4
  • Video-documented upper endoscopy with biopsy: Confirm diagnosis and obtain tissue for biomarker testing 4
  • Endoscopic ultrasound: If locally advanced features or uncertain resectability 4
  • Consider diagnostic laparoscopy if peritoneal metastases suspected but not confirmed on imaging

Organ Function and Performance Status:

  • Complete blood count: Assess for anemia, neutropenia, thrombocytopenia
  • Comprehensive metabolic panel: Liver function (AST, ALT, bilirubin, alkaline phosphatase), renal function (creatinine, eGFR), electrolytes
  • ECOG performance status: Must be 0-2 for most chemotherapy regimens
  • Cardiac function: Baseline echocardiogram or MUGA scan if planning trastuzumab (monitor LVEF)
  • Nutritional assessment: Weight, albumin, prealbumin—early nutritional support improves outcomes 5

Additional Baseline Tests:

  • Hepatitis B and C screening: Required before immunotherapy
  • Pregnancy test: For women of childbearing potential
  • Tumor markers: CEA, CA 19-9 (optional, for monitoring response)

Second-Line Treatment Options

If first-line therapy fails:

Ramucirumab + paclitaxel is the preferred second-line regimen 2. The RAINBOW trial demonstrated improved OS, PFS, and ORR with this combination versus paclitaxel alone 2.

Alternative second-line options include:

  • Ramucirumab monotherapy (REGARD trial showed OS benefit but limited response rates) 2
  • FOLFIRI (limited data) 2
  • Taxane or irinotecan monotherapy 2

For MSI-H tumors progressing after chemotherapy, pembrolizumab remains highly effective in second-line 2.


Third-Line Treatment

Trifluridine/tipiracil has the strongest evidence from the phase III TAGS trial 2. Alternative options include taxane or irinotecan if not previously used 2.

For HER2-positive disease progressing on trastuzumab, trastuzumab deruxtecan showed survival benefit in phase II trials 2.


Critical Pitfalls to Avoid

  1. Do not start any chemotherapy without HER2, PD-L1, and MSI testing—you will miss opportunities for highly effective targeted/immune therapy
  2. Do not use pembrolizumab in MSI-H patients with chemotherapy—monotherapy is superior 2
  3. Do not assume all metastatic disease is incurable—oligometastatic patients may benefit from conversion therapy after excellent response to systemic therapy, though this remains investigational 2
  4. Do not delay early supportive care—symptom management and nutritional support are associated with 3-month survival benefit 5
  5. Verify cardiac function before trastuzumab—cardiotoxicity monitoring is mandatory

References

Guideline

gastric cancer, version 2.2025, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Research

Chemotherapy for advanced gastric cancer.

The Cochrane database of systematic reviews, 2017

Research

[Diagnosis and treatment of gastric cancer].

Deutsche medizinische Wochenschrift (1946), 2010

Research

Gastric Cancer: A Review.

JAMA, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.